Please join us for our three-part webinar series on advances in the management of chronic myeloid leukemia (CML) patients and what the implications are for BCR-ABL transcript monitoring based on these developments.
The Evolution of CML Patient Care and the Promise of Treatment-Free Remission
Prof. Dr. Med. Martin Müller
CEO, Institute for Hematology and Oncology (IHO GmbH)
Analytical Validation of a BCR-ABL1 Monitoring System that Surpasses Current Testing Requirements
Justin Brown, PhD
How the QuantideX® qPCR BCR-ABL IS Kit Provides a Simple, Sensitive, and Scalable BCR-ABL Monitoring Solution for Our Laboratory
Guy Wayne Novotny, PhD
Director of Hematology / Molecular Pathology Departments,
Please register by entering your information below.